Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 97.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,937 shares of the biopharmaceutical company’s stock after selling 115,343 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Regeneron Pharmaceuticals were worth $1,863,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in REGN. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 31 shares in the last quarter. Tompkins Financial Corp bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. Curat Global LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $32,000. Finally, American National Bank & Trust bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $44,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $700.00 to $580.00 in a research note on Friday, May 30th. UBS Group increased their price target on Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the company a “neutral” rating in a research note on Friday, July 11th. Citigroup decreased their price target on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating for the company in a research note on Monday, June 2nd. Argus lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Finally, Robert W. Baird decreased their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $837.61.

Regeneron Pharmaceuticals Trading Up 2.0%

Regeneron Pharmaceuticals stock opened at $572.39 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The firm has a market capitalization of $61.80 billion, a PE ratio of 14.57, a PEG ratio of 2.11 and a beta of 0.33. The business’s 50-day simple moving average is $543.59 and its 200-day simple moving average is $611.77.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the prior year, the firm earned $9.55 earnings per share. The company’s revenue was down 3.7% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.61%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.